Storys zum Thema Pharmakologie

Strides Pharma International AG

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

Helmholtz Munich

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

SHL Medical

2

SHL Medical announces plans to establish SHL Advantec

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

PNO Innovation GmbH

Event Announcement: VIROFIGHT Hybrid Symposium

Epitomee Medical

Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at PODD 2024 Conference

Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...

Norgine GmbH

Norgine Announces Appointment of New CEO Janneke van der Kamp

London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...

RHEACELL GmbH und Co. KG

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

Epitomee Medical

Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device

Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...

Sysmex Europe SE

2

Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.

INSIGHTEC; Charles River Laboratories International, Inc.

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

Wilmington, Mass., Miami and Haifa, Israel (ots/PRNewswire) - Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform ...

Fördergesellschaft IZB mbH

2

Record financing rounds at the Munich biotech hub

STADA Arzneimittel AG

Press release: STADA continues strong growth journey in the first half of 2024

Acousia Therapeutics GmbH

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...

Grünenthal Group

2

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients

Gerresheimer AG

10

Gerresheimer: New pictures available

STADA Arzneimittel AG

Press release: Alvotech and STADA add to strategic alliance through denosumab partnership

Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...

STADA Arzneimittel AG

Press release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo

STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...

PNO Innovation GmbH

canSERV invites applications for "Revolutionising Cancer Patient Care"

PNO Innovation GmbH

3

canSERV invites applications for "Revolutionising Cancer Patient Care"

STADA Arzneimittel AG

Press release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey

STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...